Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?

Yusuf A Haggag, Nahla E El-Ashmawy, Kamal M Okasha, Yusuf A Haggag, Nahla E El-Ashmawy, Kamal M Okasha

Abstract

SARS-CoV-2 or COVID-19 is representing the major global burden that implicated more than 4.7 million infected cases and 310 thousand deaths worldwide in less than 6 months. The prevalence of this pandemic disease is expected to rise every day. The challenge is to control its rapid spread meanwhile looking for a specific treatment to improve patient outcomes. Hesperidin is a classical herbal medicine used worldwide for a long time with an excellent safety profile. Hesperidin is a well-known herbal medication used as an antioxidant and anti-inflammatory agent. Available shreds of evidence support the promising use of hesperidin in prophylaxis and treatment of COVID 19. Herein, we discuss the possible prophylactic and treatment mechanisms of hesperidin based on previous and recent findings. Hesperidin can block coronavirus from entering host cells through ACE2 receptors which can prevent the infection. Anti-viral activity of hesperidin might constitute a treatment option for COVID-19 through improving host cellular immunity against infection and its good anti-inflammatory activity may help in controlling cytokine storm. Hesperidin mixture with diosmin co-administrated with heparin protect against venous thromboembolism which may prevent disease progression. Based on that, hesperidin might be used as a meaningful prophylactic agent and a promising adjuvant treatment option against SARS-CoV-2 infection.

Keywords: Anti-viral activity; COVID-19; Hesperidin; Immunity; Prophylaxis; SARS-CoV-2; Treatment; Viral entry.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Figures

Fig. 1
Fig. 1
Effect of hesperidin on prophylaxis and treatment of COVID-19.

References

    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. novel coronavirus in Wuhan China. Lancet. 2019;395(2020):497–506.
    1. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473.
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2019;382(2020):727–733.
    1. Chan J.F.-W., Yuan S., Kok K.-H., To K.K.-W., Chu H., Yang J. novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2019;395(2020):514–523.
    1. Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;104787
    1. Mani Mishra P., Uversky V.N., Nandi C.K. Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2. Med Hypotheses. 2020;140
    1. Zanwar A.A., Badole S.L., Shende P.S., Hegde M.V., Bodhankar S.L. Chapter 76 – Cardiovascular effects of hesperidin: a flavanone glycoside. In: Watson R.R., Preedy V.R., Zibadi S., editors. Polyphenols in Human Health and Disease. Academic Press; San Diego: 2014. pp. 989–992.
    1. Jadeja R.N., Devkar R.V. Chapter 47 – Polyphenols and flavonoids in controlling non-alcoholic steatohepatitis. In: Watson R.R., Preedy V.R., Zibadi S., editors. Polyphenols in Human Health and Disease. Academic Press; San Diego: 2014. pp. 615–623.
    1. Dong W., Wei X., Zhang F., Hao J., Huang F., Zhang C. A dual character of flavonoids in influenza A virus replication and spread through modulating cell-autonomous immunity by MAPK signaling pathways. Sci Rep. 2014;4:7237.
    1. Nagasako-Akazome Y. Chapter 58 - Safety of high and long-term intake of polyphenols. In: Watson R.R., Preedy V.R., Zibadi S., editors. Polyphenols in Human Health and Disease. Academic Press; San Diego: 2014. pp. 747–756.
    1. Meyer O.C. Safety and security of daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology. 1994;45:579–584.
    1. Bao L., Deng W., Huang B., Gao H., Liu J., Ren L. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020
    1. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e278.
    1. Wu C., Liu Y., Yang Y., Zhang P., Zhong W., Wang Y. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B. 2020
    1. L. Huang, Y. Shi, B. Gong, L. Jiang, X. Liu, J. Yang, J. Tang, C. You, Q. Jiang, B. Long, T. Zeng, M. Luo, F. Zeng, F. Zeng, S. Wang, X. Yang, Z. Yang, Blood single cell immune profiling reveals the interferon-MAPK pathway mediated adaptive immune response for COVID-19, medRxiv, (2020) 2020.2003.2015.20033472.
    1. Coperchini F., Chiovato L., Croce L., Magri F., Rotondi M. The Cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020
    1. Xiao S., Liu W., Bi J., Liu S., Zhao H., Gong N. Anti-inflammatory effect of hesperidin enhances chondrogenesis of human mesenchymal stem cells for cartilage tissue repair. J. Inflamm. (London, England) 2018;15:14.
    1. Fu Z., Chen Z., Xie Q., Lei H., Xiang S. Hesperidin protects against IL-1β-induced inflammation in human osteoarthritis chondrocytes. Exp. Therap. Med. 2018;16:3721–3727.
    1. Homayouni F., Haidari F., Hedayati M., Zakerkish M., Ahmadi K. Blood pressure lowering and anti-inflammatory effects of hesperidin in type 2 diabetes; a randomized double-blind controlled clinical trial. Phytotherapy Res. PTR. 2018;32:1073–1079.
    1. R.J. Jose, A. Manuel, COVID-19 cytokine storm: the interplay between inflammation and coagulation, The Lancet Respiratory Medicine, (2020).
    1. Tsimoyiannis E.C., Floras G., Antoniou N., Papanikolaou N., Siakas P., Tassis A. Low-molecular-weight heparins and Daflon for prevention of postoperative thromboembolism. World J Surg. 1996;20:968–971. discussion 972.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere